Pharmacokinetics and Pharmacodynamics Practice Questions

Q: If the clearance of a drug equals its renal plasma flow, what does it imply about the drug's handling by the kidneys?

The drug is actively secreted into the renal tubules.. The concept of **Renal Clearance ($CL_r$)** is a measure of the volume of plasma cleared of a drug per unit of time [3]. To understand how a drug is handled by the kidney, we compare its clearance to the **Glomerular Filtration Rate (GFR)** and **Renal Plasma Flow (RPF)**. 1. **Why Option B is Correct:** Normal GFR is approximately **125 mL/min**, while Renal Plasma Flow (RPF) is approximately **650 mL/min**. If a drug's clearance equals the RPF, it means that *all* the plasma passing through the kidney is being stripped of the drug in a single pass [2]. Since only 20% of plasma is filtered at the glomerulus, the remaining 80% must be cleared via **active tubular secretion** in the proximal tubules to reach a clearance value equal to the RPF [1]. 2. **Why Other Options are Incorrect:** * **Option A:** If a drug is actively reabsorbed (like glucose or certain electrolytes), its clearance will be significantly **lower than the GFR** ($<125$ mL/min) [1]. * **Option C:** If a drug undergoes only filtration with no secretion or reabsorption (like **Inulin**), its clearance will **equal the GFR** (~125 mL/min) [3]. **High-Yield NEET-PG Pearls:** * **Inulin Clearance:** The gold standard for measuring GFR ($CL = GFR$) [3]. * **Creatinine Clearance:** Slightly overestimates GFR because it undergoes a small amount of tubular secretion. * **Para-aminohippuric acid (PAH):** The classic example of a drug where clearance equals RPF because it is both filtered and completely secreted [2]. * **Formula:** $Excretion = (Filtration + Secretion) - Reabsorption$. If Clearance > GFR, secretion is occurring [1].

Q: ED50 is a measure of:

Potency. **Explanation:** **Why Potency is Correct:** **Potency** refers to the amount or concentration of a drug required to produce a specific intensity of effect. It is measured by the **ED50 (Median Effective Dose)**, which is the dose required to produce a specified therapeutic response in 50% of the population. On a Dose-Response Curve (DRC), potency is represented by the position of the curve along the X-axis (dose). A drug that achieves ED50 at a lower dose is considered more potent. **Why Other Options are Incorrect:** * **Toxicity:** This is measured by the **TD50** (Median Toxic Dose) or **LD50** (Median Lethal Dose). While ED50 relates to the therapeutic effect, TD50 relates to adverse or lethal effects. * **Safety:** The safety of a drug is determined by the **Therapeutic Index (TI)**, calculated as the ratio of **LD50/ED50**. A higher TI indicates a wider margin of safety. * **Efficacy:** This refers to the maximum effect (Emax) a drug can produce, regardless of dose. On a DRC, efficacy is represented by the height (Y-axis) of the curve. A drug can be highly potent but have low efficacy, or vice versa. **High-Yield Clinical Pearls for NEET-PG:** * **Potency vs. Efficacy:** Efficacy is clinically more important than potency. For example, Furosemide is more efficacious than Chlorothiazide because it can remove more fluid, even if Chlorothiazide requires a smaller dose (higher potency) to start its effect. * **Therapeutic Window:** The range between the minimum effective dose and the maximum tolerated dose. * **Standard Safety Margin:** Calculated as `[(LD1 - ED99) / ED99] × 100`. This is a more rigorous measure of safety than the Therapeutic Index.

Q: The pharmacokinetic properties of a new antihistamine are being studied in normal volunteers during phase I clinical trials. The clearance and half-life of the drug are determined to be 4.0 L/hour and 10 hours, respectively. Which of the following values is the approximate volume of distribution for this drug?

60 L. ### Explanation **1. Why the Correct Answer is Right** The volume of distribution ($V_d$) is a theoretical volume that relates the amount of drug in the body to its concentration in the plasma. To solve this, we use the fundamental pharmacokinetic relationship between **Clearance ($CL$)**, **Half-life ($t_{1/2}$)**, and **Volume of Distribution ($V_d$)**: $$t_{1/2} = \frac{0.693 \times V_d}{CL}$$ Rearranging the formula to solve for $V_d$: $$V_d = \frac{t_{1/2} \times CL}{0.693}$$ **Calculation:** * $CL = 4.0 \text{ L/hr}$ * $t_{1/2} = 10 \text{ hours}$ * $V_d = \frac{10 \times 4.0}{0.693} \approx \frac{40}{0.7} \approx 57.14 \text{ L}$ The value **60 L** (Option D) is the closest approximation. **2. Why the Incorrect Options are Wrong** * **Option A (0.06 L):** This value is physiologically impossible for an adult and likely results from a decimal error in calculation. * **Option B (14 L):** This represents the extracellular fluid volume. A drug with this $V_d$ would be restricted to plasma and interstitial fluid. * **Option C (45 L):** This represents total body water (TBW). While closer, it does not match the mathematical result derived from the provided clearance and half-life. **3. Clinical Pearls & High-Yield Facts for NEET-PG** * **$V_d$ Interpretation:** If $V_d$ is low (approx. 3–5 L), the drug is confined to the vascular compartment (e.g., Warfarin). If $V_d$ is high (>42 L), the drug is sequestered in tissues (e.g., Digoxin, Chloroquine). * **Loading Dose:** $V_d$ is the primary determinant of the **Loading Dose** ($LD = V_d \times C_{ss}$). * **Clearance:** $CL$ is the primary determinant of the **Maintenance Dose**. * **Half-life:** It takes approximately **4 to 5 half-lives** to reach steady-state concentration ($C_{ss}$) and the same amount of time to eliminate the drug from the body after stopping.

Q: What does the ratio of LD50/ED50 represent?

Therapeutic index. ### Explanation **Therapeutic Index (TI)** is a quantitative measurement of the relative safety of a drug. It is calculated as the ratio of the **Median Lethal Dose (LD50)**—the dose that kills 50% of the test population—to the **Median Effective Dose (ED50)**—the dose that produces the desired therapeutic effect in 50% of the population. * **Formula:** $TI = LD50 / ED50$ * A higher TI indicates a wider margin of safety, meaning a much larger dose is required to cause toxicity than to produce a cure. **Analysis of Incorrect Options:** * **B. Bioavailability:** This refers to the fraction of an administered drug that reaches the systemic circulation in an unchanged form. It is determined by comparing plasma concentration-time curves (AUC) of oral vs. IV administration. * **C. Potency:** This refers to the amount of drug (dose) required to produce an effect of a given intensity. It is represented by the position of the Dose-Response Curve (DRC) on the x-axis (leftward shift = higher potency). * **D. Efficacy:** This is the maximum response ($E_{max}$) achievable by a drug, regardless of dose. It is represented by the height of the DRC on the y-axis. **High-Yield NEET-PG Pearls:** 1. **Certain Safety Factor:** Since LD50/ED50 only looks at the median, a more clinically relevant ratio is $LD1 / ED99$ (the ratio of the dose that kills 1% to the dose that is effective in 99%). 2. **Narrow Therapeutic Index Drugs:** These require **Therapeutic Drug Monitoring (TDM)** because their therapeutic and toxic doses are very close. * *Mnemonic:* **W**arfarin, **A**ntiepileptics (Phenytoin), **D**igoxin, **L**ithium, **T**heophylline (**W**ith **A** **D**igital **L**i**T**). 3. For human clinical use, **TD50** (Median Toxic Dose) is often used instead of LD50.

Q: A pharmacologist is determining the pharmacokinetic parameters of a novel antibiotic. The drug is a weak organic acid with a pKa of 3.0. Assuming a pH of 2.0 in the stomach, approximately what percent of the drug will be in a form that can be rapidly absorbed from the stomach?

90%. ### Explanation **1. Understanding the Correct Answer (D: 90%)** The absorption of a drug across biological membranes depends on its ionization state; only the **non-ionized (lipid-soluble)** form can be rapidly absorbed. This relationship is governed by the **Henderson-Hasselbalch equation**. For a **weak acid**: $pH - pKa = \log \frac{[Ionized]}{[Non-ionized]}$ Plugging in the values: * $2.0 - 3.0 = \log \frac{[I]}{[NI]}$ * $-1 = \log \frac{[I]}{[NI]}$ * $10^{-1} = \frac{[I]}{[NI]} \Rightarrow \frac{1}{10} = \frac{[I]}{[NI]}$ This means there is **1 part ionized** for every **10 parts non-ionized**. To find the percentage of the absorbable (non-ionized) form: $\frac{NI}{Total} \times 100 = \frac{10}{1 + 10} \times 100 = \frac{10}{11} \times 100 \approx \mathbf{90.9\%}$ **2. Why Other Options are Incorrect** * **A & B (60%, 50%):** These values would occur if the pH were closer to the pKa. When $pH = pKa$, the drug is 50% ionized and 50% non-ionized. * **C (99%):** This would occur if the pH were 2 units below the pKa (i.e., pH 1.0). A difference of 1 pH unit results in a 10:1 ratio (~90%), while 2 units result in a 100:1 ratio (~99%). **3. Clinical Pearls & High-Yield Facts** * **The "Like in Like" Rule:** Weak acids are better absorbed in acidic mediums (stomach), and weak bases are better absorbed in basic mediums (intestine). * **Ion Trapping:** This principle is used clinically to treat toxicity. To excrete a weak acid (e.g., Aspirin), we **alkalinize the urine** with Sodium Bicarbonate. This increases the ionized fraction in the renal tubule, "trapping" the drug in the urine and preventing reabsorption. * **Rule of Thumb:** If $pH - pKa = 1$, the ratio is 90:10. If the difference is 2, the ratio is 99:1. If the difference is 3, the ratio is 99.9:0.1.

Q: Hofmann elimination is defined as:

Inactivation of a drug through molecular rearrangement.. ### Explanation **Hofmann elimination** is a unique pharmacokinetic process where a drug undergoes spontaneous non-enzymatic degradation in the plasma and tissues. **1. Why Option D is Correct:** The correct answer is **inactivation through molecular rearrangement**. Unlike most drugs that require hepatic enzymes or renal clearance, drugs undergoing Hofmann elimination break down spontaneously due to the specific pH and temperature of the body. This involves a chemical rearrangement (specifically, a base-catalyzed elimination) that splits the molecule into inactive metabolites. **2. Why Other Options are Incorrect:** * **Option A:** This describes **biotransformation** (metabolism), typically occurring in the liver via Cytochrome P450 enzymes. Hofmann elimination is specifically *non-enzymatic*. * **Option B:** This refers to **renal excretion**, the primary route for water-soluble drugs like aminoglycosides. * **Option C:** This refers to **biliary or fecal excretion**, common for large molecular weight compounds or unabsorbed drugs. **3. Clinical Pearls & High-Yield Facts for NEET-PG:** * **Prototype Drug:** **Atracurium** and its isomer **Cisatracurium** (Skeletal muscle relaxants). * **Clinical Advantage:** Because it does not rely on the liver or kidneys, Atracurium is the **neuromuscular blocker of choice in patients with hepatic or renal failure**. * **Factors Affecting Rate:** Since it is a chemical reaction, the rate of Hofmann elimination increases with **Hyperthermia** and **Alkalosis** (high pH), and decreases with Hypothermia and Acidosis. * **Metabolite Note:** The breakdown of Atracurium produces **Laudanosine**, which can cross the blood-brain barrier and potentially cause seizures (though this is less common with Cisatracurium).

Question 1

Gentamicin has a half-life of 2-3 hours in plasma, but it accumulates in the kidney, prolonging its half-life to 53 hours. What is this prolonged half-life called?

Accepted Answer

Terminal half-life

Answer

Secondary half-life

Answer

Zero order half-life

Answer

First order half-life

Question 2

If the clearance of a drug equals its renal plasma flow, what does it imply about the drug's handling by the kidneys?

Accepted Answer

The drug is actively secreted into the renal tubules.

Answer

The drug is actively reabsorbed in the renal tubules.

Answer

The drug undergoes neither significant secretion nor reabsorption in the renal tubules.

Answer

None of the above.

Question 3

Which of the following is true for the receptor action of a drug?

Accepted Answer

An antagonist has affinity but no intrinsic activity for the receptor.

Answer

An antagonist has both intrinsic activity and affinity for the receptor.

Answer

A partial antagonist has no affinity or intrinsic activity for the receptor.

Answer

Intrinsic activity and affinity are not important for drug action.

Question 4

ED50 is a measure of:

Accepted Answer

Potency

Answer

Toxicity

Answer

Safety

Answer

Efficacy

Question 5

Which of the following is NOT an example of nonlinear kinetics?

Accepted Answer

Metabolism of diazepam

Answer

Metabolism of phenytoin

Answer

Biliary secretion of bromosulfthalein (BSP)

Answer

Glomerular filtration of naproxen

Question 6

The pharmacokinetic properties of a new antihistamine are being studied in normal volunteers during phase I clinical trials. The clearance and half-life of the drug are determined to be 4.0 L/hour and 10 hours, respectively. Which of the following values is the approximate volume of distribution for this drug?

Accepted Answer

60 L

Answer

0.06 L

Answer

14 L

Answer

45 L

Question 7

What does the ratio of LD50/ED50 represent?

Accepted Answer

Therapeutic index

Answer

Bioavailability

Answer

Potency

Answer

Efficacy

Question 8

A pharmacologist is determining the pharmacokinetic parameters of a novel antibiotic. The drug is a weak organic acid with a pKa of 3.0. Assuming a pH of 2.0 in the stomach, approximately what percent of the drug will be in a form that can be rapidly absorbed from the stomach?

Accepted Answer

90%

Answer

60%

Answer

50%

Answer

99%

Question 9

Therapeutic drug monitoring of plasma concentrations of antihypertensive drugs is NOT practiced because:

Accepted Answer

It is easier to measure the clinical effect of these drugs.

Answer

Determination of plasma levels of these drugs is a tedious and lengthy process.

Answer

The antihypertensive effect does not increase linearly with the dose.

Answer

All antihypertensive drugs are prodrugs.

Question 10

Hofmann elimination is defined as:

Accepted Answer

Inactivation of a drug through molecular rearrangement.

Answer

Inactivation of a drug by a metabolizing enzyme.

Answer

Unchanged excretion of a drug by the kidney.

Answer

Excretion of a drug in the feces.

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?